Translating evidence honestly.
For families currently caught between heavy psychiatric medications — the kind that calm a child by sedating them — and no medical help at all, the science around CBDV is a meaningful new direction. It deserves to be reported plainly, without hype.
The published research on cannabidivarin and autism has been quietly accumulating for over a decade. There are imaging studies in adults, animal studies across multiple related conditions, biomarker findings replicated in two countries, an active clinical trial in children, and a major pharmaceutical company holding patent rights. It's a coherent body of evidence pointing in a hopeful direction.
But none of that body of evidence is easy for a family to find or read. It's published in journals behind paywalls, written in clinical jargon, and scattered across five different research traditions. Families who go looking on their own end up either misled by oversimplified marketing — most of it for products that aren't actually CBDV — or frozen out by language that wasn't written for them.
The Center for Cannabidivarin Innovation and Advocacy exists to close that gap. We translate the published research honestly, support the work that's still needed, and give families and clinicians a way to follow the science as it unfolds — without overselling and without underselling.
Autism is not a single condition with a single cause, and CBDV will not be a single cure. But the body of work that's already been done points in a meaningful direction — and that direction deserves to be reported plainly, without hype.
The principles we operate on.
Five commitments that shape everything we publish.
Every claim links to its source. If we tell you a study found something, you can click through and read the actual paper. We never paraphrase research without showing the trail back to where it came from.
We tell you where the evidence stops. Promising research can become hype quickly. We deliberately mark what's known, what's pointing in a hopeful direction, and what hasn't been answered yet. Honesty about the limits is what makes the rest of it trustworthy.
We write in plain language, not clinical jargon. If a parent can't read a sentence and understand what it means, we've failed. Big words don't make the science more rigorous — they make it less accessible.
We are not a product company. We don't sell CBDV, recommend brands, or take partnerships from anyone selling supplements. Our job is to report what the science says — not to direct anyone toward any specific product.
We are not your doctor. Nothing on this site is medical advice. Anything you decide to do for your child should be discussed with a clinician who knows your child's history. We can be a resource for that conversation. We can't replace it.
The people behind this.
A small group of people who have been touched personally and professionally by autism, and who believe the research base on CBDV deserves a serious, honest public-facing translation.
How to reach us.
We hear from researchers, clinicians, families, journalists, and skeptics. We try to read every message.
If you're a researcher who's worked on CBDV and we've gotten something wrong on this site — or who'd like a finding included that we've missed — we'd genuinely like to hear from you.
If you're a clinician evaluating CBDV for a patient and want to talk through what's published, we can help orient you to the literature.
If you're a parent navigating this for the first time, we can point you toward the most readable starting points and the most reputable clinical research groups currently studying CBDV.
If you're a journalist, we'll talk on or off the record and can help fact-check anything you're working on.